A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
The reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA).
Inclusion Criteria:
Are at least 18 years and ≤60 years for males (≤70 years of age for females) at the time of informed consent.
Have severe or very severe AA, as determined by all of the following:
Male or nonpregnant, nonbreastfeeding female participants.
Exclusion Criteria:
Fort Gratiot, Michigan 48059, United States
CABA, Buenos Aires C1023AAB, Argentina
Capital Federal, Buenos Aires 1425, Argentina
Ciudad Autónoma de Buenos Aires, Buenos Aires 1027, Argentina
SAN M. de Tucuman, Tucumán Province T4000AXL, Argentina
Rio de Janeiro, Rio de Janeiro 22470-220, Brazil
Porto Alegre, Rio Grande do Sul 90050-170, Brazil
Beijing, Beijing Municipality 100050, China
Hangzhou, Zhejiang 310052, China
Ramat Gan, Central District 5262100, Israel
Haifa, Northern District 3109601, Israel
Bunkyo-ku, Tokyo 113-8431, Japan
Koto-ku, Tokyo 136-0075, Japan
Shinjuku-ku, Tokyo 160-0023, Japan
Dongjak-gu, Seoul-teukbyeolsi [Seoul] 07061, South Korea